{"Clinical Trial ID": "NCT00332709", "Intervention": ["INTERVENTION 1:", "- Letrozole", "Letrozole 2.5 mg/day for 3 years", "INTERVENTION 2:", "- Letrozole + zoledronic acid", "Letrozole 2.5mg/day for 3 years plus zoledronic acid 4mg every 6 months"], "Eligibility": ["Incorporation criteria:", "Postmenopausal compassionate women with exploitable primary breast cancer after 4 to 6 years of tamoxifen treatment (end of tamoxifen treatment in the last 6 months)", "0-2 (Eastern Cooperative Oncology Group)", "\u2022 Patients without severe osteoporosis at the start of the study", "No evidence of relapse at randomization", "Adequate function of bone marrow, kidneys and liver", "- Exclusion criteria:", "Estrogen- and progesterone-receptor negative or unknown status", "- Completion of adjuvant tamoxifen treatment more than 6 months prior to the start of the study", "Inflammatory breast cancer", "\u2022 Common/active dental problems, including tooth or jaw infection, dental or fixture trauma, or a common or anterior diagnosis of osteonecrosis of the jaw, bone exposed in the mouth, or slow healing after dental procedures.", "Recent (within 6 weeks) or planned dental or jaw surgery", "History of diseases affecting bone metabolism such as Paget's disease and primary superactive parathyroid", "Previous or concomitant therapies: chemotherapy in the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any other medicine known to affect the skeleton (such as calcitonin, mithramycin or gallium nitrate)", "Patients with previous or concomitant cancers (no breast cancer) in the last 5 years EXCEPT have adequately treated basal or squamous or in situ skin cancers of the cervix. Patients with other previous cancers must have been free of disease for at least 5 years.", "Patients currently receiving oral bisphosphonates should discontinue these studies at least 3 weeks prior to the start of the study.", "\u2022 Inclusion/exclusion criteria defined by an additional protocol may apply."], "Results": ["Performance measures:", "Change in bone mineral density (BMD) from the reference value at month 36", "Change in bone mineral density (BMD) measured by X-ray absorptiometry (DXA) in the lumbar spine (L1-L4). Change calculated by (Month 36 BMD-Baseline BMD)/Baseline BMD*100.", "Time limit: 36 months from baseline", "Results 1:", "Title of the arm/group: Letrozole", "Description of the arm/group: Letrozole 2.5 mg/day for 3 years", "Total number of participants analysed: 21", "Average (standard deviation)", "Unit of measure: Percentage -0.11 (0.14)", "Results 2:", "Title of the arm/group: Letrozole + zoledronic acid", "Description of the arm/group: Letrozole 2.5mg/day for 3 years plus zoledronic acid 4mg every 6 months", "Total number of participants analysed: 20", "Average (standard deviation)", "Unit of measure: Percentage 0.03 (0.08)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/40 (15.0%)", "- MYOCARDIAL ATTENTION 0/40 (0.00 %)", "ANGINE PECTORIS 0/40 (0.00 %)", "NON-STABLE ANGINE 0/40 (0.00 %)", "* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *", "SUPRAVENTRICULAR TACHYCARDIA 0/40 (0.00 %)", "1/40 (2.50%)", "PROGRESS IN CONCOMITANT DISEASES 1/40 (2.50%)", "CHOLECYSTITIS 1/40 (2.50%)", "DIVERTICULITIS 0/40 (0.00 %)", "CONTUSION 0/40 (0.00 %)", "Adverse Events 2:", "Total: 7/41 (17.07 per cent)", "NO MYOCARTIC INFARCTION 1/41 (2.44 %)", "ANGINE PECTORIS 1/41 (2.44 %)", "UNSTABLE ANGINE 1/41 (2.44 %)", "STENOSES OF CORONARY ARTERIA 1/41 (2.44 %)", "SUPRAVENTRICULAR TACHYCARDIA 1/41 (2.44 %)", "- POSITIONAL VERTIGO 0/41 (0.00 %)", "PROGRESS IN CONCOMITANT DISEASES 0/41 (0.00 %)", "CHOLECYSTITIS 0/41 (0.00 %)", "DIVERTICULITIS 1/41 (2.44%)", "CONTUSION 1/41 (2.44%)"]}